

Santen Establishes Subsidiary in China

September 29, 2005, Osaka, Japan -- Santen Pharmaceutical Co., Ltd. (President: Takakazu Morita) announced its establishment of Santen Pharmaceutical (China) Co., Ltd., a 100% subsidiary in China. Santen has received an operating license from Jiangsu Administration of Industry and Commerce.

In China, Santen has actively collected and communicated academic medical information through its three local offices in Beijing, Guangzhou and Shanghai. In addition, Santen has imported its prescription ophthalmic pharmaceuticals from Japan to market the products through local distributors. The new subsidiary Santen Pharmaceutical (China) will develop prescription ophthalmics, construct a manufacturing plant in Suzhou Industrial Park, and establish a direct sales and marketing organization, accelerating Santen's endeavors to place its products and the Santen brand into China's rapidly growing market.

Profile of the new subsidiary

Company name: Santen Pharmaceutical (China) Co., Ltd.
Address: Suzhou Industrial Park 3rd District, Suzhou, Jiangsu
Incorporated: September 21, 2005
Start of operation: January 2009 (plan)
Paid-in capital: 2.3 billion yen
Equity ownership: 100% by Santen Pharmaceutical Co., Ltd.
Representative: Takakazu Morita, Chair
(President and Chief Executive Officer, Santen Pharmaceutical Co., Ltd.)
Business: Development, manufacturing and sales of prescription ophthalmic pharmaceuticals
Headcount: Approx. 200 at start of operation
Manufacturing plant and office space:
Lot area: Approx. 30,000 sq. m.
Floor space: Approx. 7,700 sq. m.
Construction schedule: Start 2006; Complete 2007; Start operation 2009
Capacity: Approx. 20 million bottles per year